



Legislation Details (With Text)

File #: 22-502 **Version:** 1

Type: Executive Session **Status:** Agenda Ready

File created: 8/3/2022 **In control:** City Council

On agenda: 8/9/2022 **Final action:**

Title: Pursuant to Section 307B.4, Title 25, Oklahoma Statutes, consider convening in executive session to discuss an action relating to litigation against the manufacturers and distributors of opioids in an effort to hold them accountable for their marketing practices alleged to have caused public nuisance and monetary damages suffered by municipalities, specifically, the City’s pending litigation in City of Lawton v. Purdue Pharma Inc., et al, CIV-19-78 as part of In Re: National Prescription Opiate Litigation MDL No. 2804, to include a discussion and consideration for approval a potential settlement with Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc. (collectively “Janssen”), and if necessary take action in open session that may include the approval one or more resolutions and/or other documents related to any such settlement.

Sponsors:

Indexes:

Code sections:

Attachments:

Date	Ver.	Action By	Action	Result
------	------	-----------	--------	--------

ITEM TITLE:

Pursuant to Section 307B.4, Title 25, Oklahoma Statutes, consider convening in executive session to discuss an action relating to litigation against the manufacturers and distributors of opioids in an effort to hold them accountable for their marketing practices alleged to have caused public nuisance and monetary damages suffered by municipalities, specifically, the City’s pending litigation in City of Lawton v. Purdue Pharma Inc., et al, CIV-19-78 as part of In Re: National Prescription Opiate Litigation MDL No. 2804, to include a discussion and consideration for approval a potential settlement with Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc. (collectively “Janssen”), and if necessary take action in open session that may include the approval one or more resolutions and/or other documents related to any such settlement.

INITIATOR: John Ratliff, City Attorney

STAFF INFORMATION SOURCE: Timothy Wilson, Deputy City Attorney

BACKGROUND: The City Attorney desires to discuss with the Mayor and Council its ongoing opioid litigation and if necessary, take action in open session. Said discussion will include a discussion and consideration of a potential settlement with Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc. (collectively “Janssen”). The City Attorney advises the City Council that the Council should determine that disclosure of confidential communication

between the Council and the City Attorney regarding the above referenced action will seriously impair the ability of the City Attorney to protect the City's interest, and from that determination, the Council should convene in executive session to discuss this matter.

EXHIBIT: N/A

KEY ISSUES: N/A

FUNDING SOURCE: N/A

STAFF RECOMMENDED COUNCIL ACTION: Convene in executive session to discuss an action against the manufacturers and distributors of opioids in an effort to hold them accountable for their marketing practices alleged to have caused public nuisance and monetary damages suffered by municipalities, and if necessary, take action in open session.